BRIEF published on 11/28/2025 at 09:05, 6 days 20 hours ago BOS Group Reports Q3 2025 Financial Results Amid Challenging Market Financial Results Automotive Industry Revenue Decline Q3 2025 BOS Group
PRESS RELEASE published on 11/28/2025 at 09:00, 6 days 20 hours ago BOS Group issues Q3 2025 results BOS Group reports Q3 2025 results with EUR 580.4m revenue in 9M, maintaining efficiency amidst market challenges. CFO expects revenue below previous year's levels due to industry pressure Revenue Automotive Industry Efficiency Q3 2025 Results BOS Group
BRIEF published on 08/29/2025 at 09:05, 3 months 6 days ago BOS Group Reports Q2 2025 Financial Results Amid Market Challenges EBITDA Margin Revenue Decline Nordic Bond Q2 2025 Results BOS Group
PRESS RELEASE published on 08/29/2025 at 09:00, 3 months 6 days ago BOS Group issues Q2 2025 results BOS Group reports Q2 2025 results with EUR 197.3m gross revenue. Adjusted EBITDA margin at 7.7%. Nordic Bond refinancing details available online Adjusted EBITDA Nordic Bond Q2 2025 Results BOS Group Gross Revenue
Published on 12/05/2025 at 02:35, 2 hours 46 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 21 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 16 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 21 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 51 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 30 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 56 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 6 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 11 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 21 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 36 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 37 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 20 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025
